Circumvent Pharmaceuticals is seeking to address the significant unmet need of neurodegenerative disease patients. Circumvent is targeting heritable forms of neurodegeneration to enable drug discovery and development in both rare and common forms of neurodegenerative disease. Circumvent is funded by NIH/NINDS, YC Bio, Heritage Provider Network, and the Longevity Fund
| Website | http://www.circumventpharmaceuticals.com |
| Employees | 8 (3 on RocketReach) |
| Founded | 2017 |
| Industry | Biotechnology Research, Health Care, Drug Discovery, Pharmaceutical, Pharmaceuticals |
| Keywords | Neurodegenerative Diseases, Drug Discovery, Drug Development, Rare Diseases, Pharmaceutical Research, Therapeutics, Dementia Research, Alzheimers Research, Parkinsons Research, Genetic Disorders, Innovative Therapies, Biotechnology, Clinical Trials, Medical Research, Pharmaceutical, Biopharma, Patient Care |
| Competitors | ICON plc, Research Pharmaceutical Services, Syneos Health, Parexel, Medpace, Covance, Worldwide Clinical Trials, Celerion, PharmaLogics Recruiting, Clinovo +39 more (view full list) |
Looking for a particular Circumvent employee's phone or email?
Daniel Chelsky is the Chief Scientific Officer of Circumvent.
3 people are employed at Circumvent.
Circumvent is based in Portland, Oregon.